Ampio Pharmaceuticals, Inc.
AMPE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AMPE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
Market Cap
$208K
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2023.
Run Ampio Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Ampio Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$67
| Holder | Shares | Value |
|---|---|---|
| cypress capital management llc (wy) | 440 | $67 |
Short Interest
as of Apr 22, 2026- % of float
- 2.9%
- Days to cover
- 0.3
- Shares short
- 32,904
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AMPE short interestGovernance
Frequently asked questions
Who is the CEO of Ampio Pharmaceuticals, Inc.?
Mr. Michael A. Martino is the chief executive officer of Ampio Pharmaceuticals, Inc. (AMPE).
Where is Ampio Pharmaceuticals, Inc. headquartered?
Ampio Pharmaceuticals, Inc. (AMPE) is headquartered in Englewood, CO, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.